This article reviews the current evidence behind goal-directed therapy (GDT) in multiple medical settings.
INTRODUCTION
The use of goal-directed therapy (GDT) has been investigated in many different settings, including the emergency room, ICU, and operating room. The typical patient population in the emergency room and ICU include patients suffering from septic shock. In the surgical setting, higher risk procedures, such as gastrointestinal, vascular, and cardiac surgery patients are usually chosen for evaluating the potential benefits of GDT. Given the nature of these procedures, the patients are often already deemed to be at higher risk for a poor outcome regardless of the type of surgery. Therefore strategies, which may improve complications, morbidity, and mortality such as GDT are frequently explored by clinicians and researchers in an attempt to guide clinical care. This review will focus on the use of GDT in cardiac and high-risk surgery while also including evidence from other settings and surgical procedures.
TEXT OF REVIEW

Goal-directed therapy in septic shock
The implementation of GDT to clinical practice is not a new concept. It dates back many years, and remains a major focus in medicine especially in treating patients with septic shock. In 2001, Rivers et al. [1] published a study in the New England Journal of Medicine which showed an improvement in in-hospital mortality for patients randomized to a GDT group over the control group in patients presenting to the emergency room in septic shock (30.5 vs. 46.5%, P ¼ 0.009). Although this study was conducted at an urban hospital and included only 263 patients, it led to the implementation of GDT in the widely known and accepted Surviving Sepsis Campaign [2] [3] [4] . Since its publication, many studies including the recent Australasian Resuscitation In Sepsis Evaluation (ARISE) and Protocolized Care for Early Septic Shock (ProCESS) trials, have failed to demonstrate benefits of GDT as neither showed an improved mortality with its use in patients diagnosed with septic shock.
The ARISE trial randomized 1600 patients presenting to the emergency room with septic shock into either an early GDT (EGDT) or usual-care group [5 & ]. All-cause mortality at 90 days (primary outcome) was similar between groups, as was in-hospital mortality, survival time, length of hospital stay, and duration of organ support. Another similar study which included 31 emergency departments across the USA randomly assigned patients to one of three groups: 439 to protocol-based EGDT, 446 to protocol-based standard therapy (no central venous catheter placed), and 456 to usual care [6 & ]. When comparing 60-day mortality between the three groups, no difference was shown [relative risk (RR) with protocol-based therapy vs. usual care, 1.04; 95% confidence interval (CI), 0.82 to 1.31; P ¼ 0.83; RR with protocol-based EGDT vs. protocol-based standard therapy, 1.15; 95% CI, 0.88 to 1.51; P ¼ 0.31]. Several studies on GDT in the perioperative setting also lack evidence supporting its use.
Perioperative goal-directed therapy
In the Optimisation of Cardiovascular Management to Improve Surgical Outcome (OPTIMISE) study, investigators conducted a randomized controlled trial, which included 734 patients at 17 hospitals in the UK undergoing major gastrointestinal surgery [7 && ]. Patients were divided into a cardiac output guided group with intravenous fluids (IVFs) and dopexamine administration or a usual care group. The study found that the GDT group did not reduce complications or 30-day mortality when compared with the usual care group (RR 0.84, 95% CI, 0.71-1.01, P ¼ 0.7). Secondary outcomes also were not different between the two groups. A recent study, also on patients undergoing major abdominal surgery, shared similar findings to OPTIMISE. The perioperative goal-directed therapy in major abdominal surgery study was conducted across six tertiary medical centers on 142 patients and divided patients into a standard practice group or study group, which used blood pressure, cardiac index, and stroke volume to guide fluid administration and vasoactive [8 & ]. The only significant finding was a reduction in reoperation in the GDT group (5.6 vs 15.7%; P ¼ 0.049). No significant differences in complications, mortality, or length of stay were found. To date, OPTIMISE is the largest randomized, controlled trial on GDT in surgical patients and no statistically significant benefit for patients randomized to receive GDT was shown. Other studies and the recent perioperative goal-directed therapy in major abdominal surgery study have shown similar results. But some systematic studies and metaanalyses go against these results and have demonstrated several advantages to GDT in the operating room.
A meta-analysis of 14 randomized controlled trials on GDT and published in Critical Care showed a decrease in postoperative morbidity (odds ratio 0.51; CI 0.34 to 0.75; P < 0.001) with reductions in infection, cardiovascular, and abdominal complications in patients receiving GDT [9 & ]. A decrease in length of stay was also shown (weighted mean difference À0.75 days; CI À1.37 to À0.12; P ¼ 0.02). Another study published in Critical Care aimed to further evaluate GDT on patients subdivided into three groups -extremely high risk, high risk, and intermediate risk of mortality as defined by mortality rates of >20%, 5 to 20%, and < 5% mortality rates respectively [10] . This clinical review included 27 trials and although mortality rate was only reduced in the extremely high-risk group (OR ¼ 0.20, 95% CI 0.09 to 0.41; P < 0.0001), complication rates were reduced in all groups (OR ¼ 0.45, 95% CI 0.34 to 0.60; P < 0.00001). Interestingly, the authors of OPTIMISE added data from their study to 37 other trials and completed a meta-analysis. The analysis suggested a lower complication rate in GDT patients (488/1548 [31.5%] vs. 614/1476 [41.6%]; RR 0.77 [95% CI, 0.71-0.83], P < 0.001), but did not demonstrate a reduction in hospital, 28-day, or 30-day mortality when comparing intervention groups to the control [7 && ]. Thus, recent randomized controlled trials do not show evidence supporting GDT, yet there are meta-analyses which do.
Goal-directed therapy in cardiac surgery
Similar to GDT in septic shock, its use in cardiac surgery dates back many years. A study on 60 patients undergoing elective cardiac surgery conducted 20 years ago, aimed to decipher the role of intravascular volume expansion on gut mucosal perfusion [11] . The protocol group received boluses of 200 ml 6% hydroxyethyl starch every 15 min with a goal to maintain maximum stroke volume as measured with an esophageal Doppler. The primary endpoint of gastric mucosal perfusion showed a
KEY POINTS
The use of GDT may be beneficial depending on the clinical setting.
More evidence supporting the use of GDT is necessary before it can be considered standard of care.
The verdict on GDT has yet to be defined. benefit of lowering the incidence of hypoperfusion in the protocol group (7 vs 56%, P < 0.001). Reductions in complications, hospital stay, and time in the ICU were also shown in the study. The positive results seen in the secondary outcomes of this study led the way for future trials in GDT, which concentrated on the reduction in complications, morbidity, and mortality when using GDT in cardiac surgery.
One of the larger randomized, controlled trials investigating GDT in cardiac surgery enrolled 403 patients with a goal of maximizing oxygen delivery and consumption in the protocol group [12] . The protocol group had a goal central venous oxygen saturation (SvO2) >70% and lactate <2.0 mmol/l utilizing dobutamine infusions up to 15 mcg/kg/ min. The study found both median hospital stay (6 vs. 7 days, P < 0.05) and morbidity was lower (1.1 vs 6.1%, P < 0.01) in the protocol group. Although most GDT regimens begin in the operating room, some groups have looked into initiating them early in the postoperative period. McKendry et al. [13] evaluated a nurse led protocol on 174 patients undergoing cardiac surgery in which the study group used an esophageal Doppler to maintain stroke index >35 ml/m 2 . Mortality between the GDT group and standard care group was not different, but a reduction in median and mean hospital stay was shown (7 vs. 9 days, P ¼ 0.02; 11.4 vs. 13.9 days, respectively). These studies were able to show significant differences when comparing GDT to standard care. Other trials in cardiac surgery have not.
A much smaller randomized controlled trial which included 27 patients undergoing coronary artery bypass grafting (CABG) set goals of central venous pressure (CVP) 6-8 mmHg, mean arterial pressure (MAP) 90-105 mmHg, normal arterial blood gas, hematocrit >30, and urine output >1 ml/kg/h in the GDT group [14] . Both IVFs and inotropes/vasodilators were used to obtain these hemodynamic goals. Trends toward supporting GDT were shown in duration of ventilation (13.8 AE 3.2 vs. 20.7 AE 7.1 h), days of use of inotropic agents (1.6 AE 0.9 vs. 3.8 AE 1.6 d), ICU stay (2.6 AE À0.9 vs. 4.9 AE 1.8 d) and hospital stay (5.6 AE 1.2 vs. 8.9 AE 2.1 d), but these findings were not significant (P > 0.05 for every outcome). This was a small study and likely not powered adequately to show a difference if one existed. Another small randomized study took 40 patients undergoing offpump CABG and divided them into advanced monitoring or conventional monitoring groups [15] . Each group received inotropes, vasopressors, and/or IVFs to maintain CVP, MAP and HR, but in addition to these parameters, the advanced monitoring group had specific targets for intrathoracic blood volume index, MAP, HR, central venous oxygen saturation SvO2, and CI. The findings showed that the advanced monitoring group had a decreased time to ICU discharge and a reduction in hospital stay by 15 and 25%, respectively (P < 0.04). Both Pölönen et al. and Mckendry et al. had sufficient power to show a difference, but many other studies have lacked adequate sample sizes, and therefore produced mixed results.
A systematic review with meta-analysis on GDT studies including both cardiac and vascular surgery patients used 11 articles (five cardiac and six vascular) with a total of 1179 patients [16] . When including both studies on cardiac and vascular patients, perioperative GDT did not reduce mortality (pooled OR 0.87; 95% CI 0.37-2.02). But although no effect on complications was observed in vascular patient studies (OR, 0.84; 95% CI 0.45-1.56; P ¼ 0.58), complications were reduced in the GDT groups for cardiac studies (OR 0.34; 95% CI 0.18-0.63; P ¼ 0.0006). Another meta-analysis that included only five studies which met their inclusion criteria analyzed data on 699 patients [17] . This study found GDT to reduce postoperative complication rate and also length of stay in the hospital (OR 0.33, 95% CI 0.15-0.73; P ¼ 0.006, mean difference À2.44, 95% CI À4.03 to À0.84; P ¼ 0.003, respectively). The previous studies are slightly dated, but investigators continue to research the effects and different methods of GDT in cardiac surgery.
A recent prospective, controlled trial randomized 100 elective CABG patients to a study group which utilized an endotracheal cardiac output monitor to measure stroke volume variation (SVV) and CI to guide therapy or a control group which received standard care [18 & ]. Only a reduction in time to extubation was significant (510 vs. 570 min, P ¼ 0.05) whereas other outcomes, such as length of stay, mortality, and complications were not statistically different between the groups. Some authors believe the use of pulmonary artery catheter (PAC) measurements to direct care after cardiac surgery is not as effective as once thought and may be associated with several dangerous complications [19] . A study which aimed to compare GDT utilizing either a PAC or noninvasive cardiac output monitor (NICOM) enrolled and randomized 59 patients undergoing heart valve surgery to the two groups [20] . One group used a goal pulmonary capillary wedge pressure taken with a PAC, whereas the other group directed therapy on changes in stroke volume index after passive leg raise utilizing a NICOM. Length of stay was not different between the groups. The PAC group required more epinephrine and ventilator care (5 vs. 0 pts, P ¼ 0.019; 6 vs. 1 pts, P ¼ 0.044, respectively) than the NICOM group and also required more colloid (1652 vs. 11430 ml, P ¼ 0.004). As with the PAC, some clinicians question the accuracy and reliability of the NICOM.
CONCLUSION
The use of GDT in septic shock has been advocated for and accepted for many years. Recent trials such as ARISE, ProCESS, and also OPTIMISE have not shown significant benefit of GDT with regards to morbidity or mortality. Given the influence and recognition of the Surviving Sepsis Campaign, clinicians have become more aware of the necessity for fluids in this patient population, which was not present during the Rivers et al. trial. This may have impacted the 'control groups' in the more recent trials that have shown no true benefits to GDT. Interestingly, the use of GDT is more widely accepted in the septic population than high-risk surgical patients despite data suggesting no benefit when GDT is utilized in sepsis whereas some recent studies in high-risk surgery support GDT. A lack of uniformity with study design may be a factor. For years investigators have come up with many different algorithms and guidelines trying to improve patient outcomes with the use of GDT (see Table 1 ). The results are definitely mixed when sifting through the studies, but several meta-analyses have shown multiple benefits. The issues with completing a meta-analysis on GDT studies are the inconsistencies with both the hemodynamic variables which guide therapy and the interventions used to achieve the desired hemodynamic ranges. From CI to SVV to CVP, no study has shown one parameter to be better than the other for guiding therapy. And for interventions, crystalloid versus colloid, inotrope versus vasopressor; there is no consensus as to which fluid or medication to choose. The use of GDT forces physicians to stick to a defined algorithm (that potentially improves outcomes), and also helps to reduce variation in care. Patient outcome is always the top priority for any doctor, but until studies aim to define the optimal hemodynamic parameter(s) and intervention(s) for GDT, the use of GDT in the perioperative setting will not be accepted by the majority. In the OPTIMISE study, investigators conducted a randomized controlled trial which included 734 patients undergoing major gastrointestinal surgery into a cardiac output guided group with IVFs and dopexamine administration or a usual care group. The study found that the GDT group did not reduce complications or 30 day mortality when compared with the usual care group. To date, OPTIMISE is the largest randomized, controlled trial on GDT in surgical patients and no statistically significant benefit for patients randomized to receive GDT was shown.
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